ReviewBioMed research international2015
Production of monoclonal antibodies in plants for cancer immunotherapy.
Review in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 46 citations in OpenAlex.
- Rapid and Cost-Effective Diagnostic Blot Assays Based on the Use of Plant-Produced Recombinant Antigens: Lessons Learned from the SARS-CoV-2 RBD Antigen.International journal of molecular sciences · 2025Article
- Plant cross-fertilization for production of dual-specific antibodies targeting both Ebola virus-like particles and HER2 protein in FGenes & genomics · 2025Article
- The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy.Journal of inflammation research · 2025Review
- Exploring the Potentiality of a Plant Platform for Monoclonal Antibody Production in Veterinary Medicine.Vaccines · 2024Article
- Production, expression, and function of dual-specific monoclonal antibodies in a single plant.Planta · 2023Article
- Effect of plant produced Anti-hIL-6 receptor antibody blockade on pSTAT3 expression in human peripheral blood mononuclear cells.Scientific reports · 2023Article
- Molecular Farming of Pembrolizumab and Nivolumab.International journal of molecular sciences · 2023Review
- Antiviral Potential of Plants against COVID-19 during Outbreaks-An Update.International journal of molecular sciences · 2022Review
- Anatomic Distribution of Intravenously Injected IgG Takes Approximately 1 Week to Achieve Stratum Corneum Saturation in Vaginal Tissues.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Functional Characterization of Pembrolizumab Produced inFrontiers in plant science · 2021Article
- Expression and in vitro function of anti-cancer mAbs in transgenic Arabidopsis thaliana.BMB reports · 2020Article
- Plant-Produced Monoclonal Antibody as Immunotherapy for Cancer.BioMed research international · 2020Review
- Future of cancer immunotherapy using plant virus-based nanoparticles.Future science OA · 2019Review
- Article
- Article
- Reconceptualizing cancer immunotherapy based on plant production systems.Future science OA · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plants are considered as an alternative platform for recombinant monoclonal antibody (mAb) production due to the improvement and diversification of transgenic techniques. The diversity of plant species offers a multitude of possibilities for the valorization of genetic resources. Moreover, plants can be propagated indefinitely, providing cheap biomass production on a large scale in controlled conditions. Thus, recent studies have shown the successful development of plant systems for the production of mAbs for cancer immunotherapy. However, their several limitations have to be resolved for efficient antibody production in plants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.